Floatz logo

PAN-FGFR TYROSINE KINASE INHIBITOR JNJ-42756493

Neoplasm

Janssen Pharmaceutical K.K.Small moleculePhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

928 Active assets in the Neoplasm cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
Astellas Pharma Inc
Phase 2BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Sanofi
Phase 4BB
Inno-206
The First Affiliated Hospital of Soochow University
Phase 2/3BB
DINITROGEN MONOXIDE
Medical College of Wisconsin
Phase 4BB
Glycopyrrolate
Medical College of Wisconsin
Phase 4BB

View all 50 →

Same molecule, other indications

PAN-FGFR TYROSINE KINASE INHIBITOR JNJ-42756493 is also rated in:

hepatocellular carcinomaDormant
B
Indicative ·
58 / 100
View asset →
lymphomaDormant
B
Indicative ·
58 / 100
View asset →
bladder transitional cell carcinomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →